TRV GP’s Larimar Therapeutics LRMR Stock Holding History

TRV GP’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-17,531	Closed	-$250K	–	4
2019 Q2	$250K	Hold	17,531	–	–	0.28%	4
2019 Q1	$576K	Hold	17,531	–	–	0.57%	4
2018 Q4	$1.04M	Hold	17,531	–	–	1.04%	4
2018 Q3	$2.46M	Hold	17,531	–	–	2.04%	4
2018 Q2	$2.15M	Hold	17,531	–	–	1.36%	4
2018 Q1	$1.57M	Hold	17,531	–	–	1.11%	5
2017 Q4	$972K	Buy	+17,531	New	+$790K	0.44%	5

Other funds holding LRMR

AVA

Atlas Venture Advisors Boston, Massachusetts $122M AUM 26.28% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

TRV GP's LRMR Position: Q3 2019 in Review

TRV GP sold out of Larimar Therapeutics (LRMR) in Q3 2019, closing a stake of 17,531 shares — an estimated $250K sold.

TRV GP first reported a position in LRMR in Q4 2017 and held it in 7 quarters. The position peaked at $2.46M in Q3 2018. 51 funds tracked by Wall St. Rank hold LRMR as of Q3 2019.

TRV GP reported no remaining Larimar Therapeutics position as of Q3 2019 after selling out during the quarter.
TRV GP sold 17,531 Larimar Therapeutics shares in Q3 2019, an estimated $250K.
TRV GP first reported a position in Larimar Therapeutics in Q4 2017 and held it in 7 quarters.
TRV GP's Larimar Therapeutics position peaked at $2.46M in Q3 2018.
51 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q3 2019.

Based on TRV GP's 13F filing for Q3 2019, filed 4 Nov 2019.